<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01119261</url>
  </required_header>
  <id_info>
    <org_study_id>COU-001A</org_study_id>
    <secondary_id>223062</secondary_id>
    <secondary_id>2009-016992-31</secondary_id>
    <nct_id>NCT01119261</nct_id>
  </id_info>
  <brief_title>EUropean Pharmacogenetics of AntiCoagulant Therapy - Acenocoumarol</brief_title>
  <acronym>EU-PACT</acronym>
  <official_title>EUropean Pharmacogenetics of AntiCoagulant Therapy - Acenocoumarol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Utrecht Institute for Pharmaceutical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Utrecht University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Newcastle University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Liverpool</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>LGC Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Democritus University of Thrace</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Elisabethinen Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Utrecht Institute for Pharmaceutical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale:

      The narrow therapeutic range and wide inter-patient variability in dose requirement make
      anticoagulation response to coumarin derivatives unpredictable. As a result, patients require
      frequent monitoring to avert adverse effects and maintain therapeutic efficacy. Polymorphisms
      in cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase complex 1 (VKORC1) jointly
      account for about 40% of the inter-individual variability in dose requirements. To date,
      several pharmacogenetic guided dosing algorithms for coumarin derivatives, predominately for
      warfarin, have been developed. However, the potential benefit of these dosing algorithms in
      terms of their safety and clinical utility has not been adequately investigated in randomised
      settings. Objective: To determine whether a dosing algorithm containing genetic information
      increases the time within therapeutic INR range during anticoagulation therapy with each of
      warfarin, acenocoumarol and phenprocoumon compared to a dosing regimen that does not contain
      this information. Secondary outcomes of the study include cost effectiveness, number of
      thromboembolic and bleeding events, time to reach stable dose and number of supratherapeutic
      INR peaks. Study design: This is a two-armed, single-blinded, randomised controlled trial. In
      one arm (intervention) patients commencing anticoagulation therapy with either warfarin,
      acenocoumarol or phenprocoumon will be dosed according to a drug-specific genotype-guided
      dosing algorithm, which is based on genetic information, clinical data and (in the monitoring
      phase) previous INR. For the other arm (control) patients will be dosed according to a
      non-genotype-guided dosing regimen which does not include genetic information. The follow-up
      period per patient is 3 months. Study population: Newly diagnosed patients of both genders
      and at least 18 years old who need anticoagulant treatment with either acenocoumarol,
      phenprocoumon or warfarin within the low intensity INR range will be included in the trial.
      Main study parameters/endpoints: The % time within therapeutic INR range in the first 3
      months of anticoagulation therapy. Nature and extent of the burden and risks associated with
      participation, benefit and group relatedness: Six extra blood samples are taken from each
      participant at the start of the study. Patients also have to attend 8 scheduled visits within
      the 3 months study period and are asked to fill in questionnaires. The genotype-guided dosing
      algorithm is anticipated to improve the accuracy of coumarin dosing and thus improve the
      safety and efficacy of anticoagulation therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent time within therapeutic INR range 2-3 during 12 weeks following the initiation of coumarin therapy</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to INR &gt; or = 4.0, which indicates overanticoagulation.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent time spent &gt; or = INR 4.0</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent time spent &lt; or = INR 2, which indicates under-anticoagulation</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach therapeutic INR defined as the time to the first INR within target range, providing that a subsequent INR &gt; or =1 week later is also within target range</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach stable dose defined as INR within target range for a period of at least 3 weeks with &lt;10% change in dose</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to and number of minor and major bleeding events</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to and number of thromboembolic events (therapeutic failure)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of coumarin sensitivity</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of coumarin resistance</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of coumarin dose adjustments</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The clinical utility of the rapid genotyping test developed by LGC</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as reported by the patient tested by the EuroQol (EQ)-5D questionnaire</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The cost-effectiveness of genotype-guided dosing for each coumarin compared with non-genotype-guided dosing</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with INR &gt; or = 4.0, which indicates overanticoagulation</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">970</enrollment>
  <condition>Venous Thromboembolism</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Non-genotype-guided dosing algorithm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype-guided dosing algorithm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Genotype-guided dosing algorithm</intervention_name>
    <description>Loading and monitoring dose according to genotype-guided dosing algorithm</description>
    <arm_group_label>Genotype-guided dosing algorithm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-genotype-guided dosing algorithm</intervention_name>
    <description>Loading and monitoring dose according to non-genotype-guided dosing algorithm</description>
    <arm_group_label>Non-genotype-guided dosing algorithm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with either venous thromboembolism (VTE) or atrial fibrillation (AF)
             requiring coumarin therapy for at least 12 weeks and a target INR in the low intensity
             range (INR range 2-3 in the United Kingdom, Sweden, Germany, Austria and Greece and
             INR 2.5-3.5 in the Netherlands)

          -  Age ≥ 18 years

          -  Ability to attend scheduled visits

          -  Signed informed consent

        Exclusion Criteria:

          -  Presence of a mechanical heart valve

          -  Severe cognitive impairment

          -  Known genotype CYP2C9 or VKORC1 at start of the study

          -  Previous or current treatment with any coumarin

          -  Pregnancy or lactation

          -  Non-eligible subject
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Democritus University of Thrace Medical School</name>
      <address>
        <city>Alexandropoulis</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utrecht University</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
    <country>Netherlands</country>
  </location_countries>
  <removed_countries>
    <country>Spain</country>
  </removed_countries>
  <reference>
    <citation>van Schie RM, Wadelius MI, Kamali F, Daly AK, Manolopoulos VG, de Boer A, Barallon R, Verhoef TI, Kirchheiner J, Haschke-Becher E, Briz M, Rosendaal FR, Redekop WK, Pirmohamed M, Maitland van der Zee AH. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics. 2009 Oct;10(10):1687-95. doi: 10.2217/pgs.09.125.</citation>
    <PMID>19842940</PMID>
  </reference>
  <reference>
    <citation>Verhoef TI, Redekop WK, Darba J, Geitona M, Hughes DA, Siebert U, de Boer A, Maitland-van der Zee AH, Barallon R, Briz M, Daly A, Haschke-Becher E, Kamali F, Kirchheiner J, Manolopoulos VG, Pirmohamed M, Rosendaal FR, van Schie RM, Wadelius M; EU-PACT Group. A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives. Pharmacogenomics. 2010 Jul;11(7):989-1002. doi: 10.2217/pgs.10.74. Review.</citation>
    <PMID>20602617</PMID>
  </reference>
  <reference>
    <citation>van Schie RM, Jorgensen AL, de Boer A, Maitland-van der Zee AH; EU-PACT study group. Systematic review of pharmacogenetic warfarin dosing. J Gen Intern Med. 2009 Oct;24(10):1171. doi: 10.1007/s11606-009-1083-9.</citation>
    <PMID>19693633</PMID>
  </reference>
  <reference>
    <citation>van Schie RM, Verhoef TI, Boejharat SB, Schalekamp T, Wessels JA, le Cessie S, Rosendaal FR, van der Meer FJ, de Boer A, Maitland-van der Zee AH. Evaluation of the effect of statin use on the acenocoumarol and phenprocoumon maintenance dose. Drug Metabol Drug Interact. 2012;27(4):229-34.</citation>
    <PMID>23096528</PMID>
  </reference>
  <reference>
    <citation>Verhoef TI, Redekop WK, Hegazy H, de Boer A, Maitland-van der Zee AH; EU-PACT group. Long-term anticoagulant effects of CYP2C9 and VKORC1 genotypes in phenprocoumon users. J Thromb Haemost. 2012 Dec;10(12):2610-2. doi: 10.1111/jth.12007.</citation>
    <PMID>23016521</PMID>
  </reference>
  <reference>
    <citation>Verhoef TI, Redekop WK, van Schie RM, Bayat S, Daly AK, Geitona M, Haschke-Becher E, Hughes DA, Kamali F, Levin LÅ, Manolopoulos VG, Pirmohamed M, Siebert U, Stingl JC, Wadelius M, de Boer A, Maitland-van der Zee AH; EU-PACT group. Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs. Pharmacogenomics. 2012 Sep;13(12):1405-17. Review.</citation>
    <PMID>22966889</PMID>
  </reference>
  <reference>
    <citation>van Schie RM, el Khedr N, Verhoef TI, Teichert M, Stricker BH, Hofman A, Buhre PN, Wessels JA, Schalekamp T, le Cessie S, van der Meer FJ, Rosendaal FR, de Boer A, Maitland-van der Zee AH, Visser LE. Validation of the acenocoumarol EU-PACT algorithms: similar performance in the Rotterdam Study cohort as in the original study. Pharmacogenomics. 2012 Aug;13(11):1239-45. doi: 10.2217/pgs.12.101.</citation>
    <PMID>22920394</PMID>
  </reference>
  <reference>
    <citation>van Schie RM, Babajeff AM, Schalekamp T, Wessels JA, le Cessie S, de Boer A, van der Meer FJ, van Meegen E, Verhoef TI, Rosendaal FR, Maitland-van der Zee AH; EU-PACT study group. An evaluation of gene-gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol. J Thromb Haemost. 2012 May;10(5):767-72. doi: 10.1111/j.1538-7836.2012.04694.x.</citation>
    <PMID>22409277</PMID>
  </reference>
  <reference>
    <citation>Verhoef TI, Redekop WK, Buikema MM, Schalekamp T, Van Der Meer FJ, Le Cessie S, Wessels JA, Van Schie RM, De Boer A, Teichert M, Visser LE, Maitland-Van Der Zee AH; EU-PACT Group. Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users. J Thromb Haemost. 2012 Apr;10(4):606-14. doi: 10.1111/j.1538-7836.2012.04633.x.</citation>
    <PMID>22252093</PMID>
  </reference>
  <reference>
    <citation>Avery PJ, Jorgensen A, Hamberg AK, Wadelius M, Pirmohamed M, Kamali F; EU-PACT Study Group. A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy. Clin Pharmacol Ther. 2011 Nov;90(5):701-6. doi: 10.1038/clpt.2011.186. Epub 2011 Sep 28.</citation>
    <PMID>22012312</PMID>
  </reference>
  <reference>
    <citation>van Schie RM, Wessels JA, le Cessie S, de Boer A, Schalekamp T, van der Meer FJ, Verhoef TI, van Meegen E, Rosendaal FR, Maitland-van der Zee AH; EU-PACT Study Group. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. Eur Heart J. 2011 Aug;32(15):1909-17. doi: 10.1093/eurheartj/ehr116. Epub 2011 Jun 2. Erratum in: Eur Heart J. 2013 Jun;34(24):1854.</citation>
    <PMID>21636598</PMID>
  </reference>
  <reference>
    <citation>van Schie RM, Wessels JA, Verhoef TI, Schalekamp T, le Cessie S, van der Meer FJ, Rosendaal FR, Visser LE, Teichert M, Hofman A, Buhre PN, de Boer A, Maitland-van der Zee AH. Evaluation of the effect of genetic variations in GATA-4 on the phenprocoumon and acenocoumarol maintenance dose. Pharmacogenomics. 2012 Dec;13(16):1917-23. doi: 10.2217/pgs.12.174.</citation>
    <PMID>23215884</PMID>
  </reference>
  <reference>
    <citation>Verhoef TI, Zuurhout MJ, van Schie RM, Redekop WK, van der Meer FJ, le Cessie S, Schalekamp T, de Boer A, Maitland-van der Zee AH. The effect of omeprazole and esomeprazole on the maintenance dose of phenprocoumon. Br J Clin Pharmacol. 2012 Dec;74(6):1068-9. doi: 10.1111/j.1365-2125.2012.04295.x.</citation>
    <PMID>22497277</PMID>
  </reference>
  <reference>
    <citation>van Schie RM, de Boer A, Maitland-van der Zee AH. Implementation of pharmacogenetics in clinical practice is challenging. Pharmacogenomics. 2011 Sep;12(9):1231-3. doi: 10.2217/pgs.11.81.</citation>
    <PMID>21919599</PMID>
  </reference>
  <reference>
    <citation>van Schie RM, Cascorbi I, Maitland-van der Zee AH. Conference Scene: Pharmacogenomics at the second PharmSciFair 2009: adverse drug reactions and clinical implementation. Pharmacogenomics. 2009 Sep;10(9):1389-91. doi: 10.2217/pgs.09.95.</citation>
    <PMID>19761363</PMID>
  </reference>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2010</study_first_submitted>
  <study_first_submitted_qc>May 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2010</study_first_posted>
  <last_update_submitted>June 17, 2013</last_update_submitted>
  <last_update_submitted_qc>June 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Utrecht Institute for Pharmaceutical Sciences</investigator_affiliation>
    <investigator_full_name>Anke-Hilse Maitland-van der Zee</investigator_full_name>
    <investigator_title>PharmD, PhD</investigator_title>
  </responsible_party>
  <keyword>Venous thromboembolism (VTE)</keyword>
  <keyword>Atrial fibrillation (AF)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anticoagulants</mesh_term>
    <mesh_term>Acenocoumarol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

